ACTRN12607000284460招募中2 期
A Phase II, Multicenter, Randomized, Double-Mask, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •2. Presence of fever at time of screening of =38.0 ºC (=100.4 ºF) taken orally, or =38.5 ºC (=101.2 ºF) taken rectally. However, this requirement is waived if the subject has a history of fever within the 24 hours prior to screening and has been administered antipyretic(s) in the 6 hours prior to screening.3. Presence of at least one respiratory symptom (cough, sore throat, or nasal symptoms) of any severity (mild, moderate, or severe)4. Presence of at least one constitutional symptom (headache, malaise, myalgia, sweats and/or chills, or fatigue) of any severity (mild, moderate, or severe)5. Onset of illness no more than 48 hours before presentation. Note: Time of onset of illness is defined as either (1) the time when the temperature (either oral or rectal) was first measured as elevated (at least one ºC of elevation-oral temperature), OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom.6. Rapid Antigen Test (RAT) performed on an adequate specimen collected from an anterior nasal swab is positive. A negative initial RAT may be repeated within one hour of obtaining a negative result. A second negative RAT result will exclude the subject from evaluation for enrollment.7. Females of childbearing potential must report one of the following:• Be surgically sterile• Have been sexually abstinent 4 weeks prior to date of screening evaluation and be willing to remain abstinent through 4 weeks after study drug administration• Use oral contraceptives or other form of hormonal birth control including hormonal vaginal rings or transdermal patches and have been using these for 3 months prior through 4 weeks after study drug administration• Use an intra-uterine device (IUD), or adequate barrier contraception (or double-barrier method such as condom or diaphragm with spermicidal gel or foam) as birth control 4 weeks prior to date of screening evaluation through 4 weeks after study drug administration.
排除标准
- •1. Women who are breast-feeding2. History of diagnosed chronic obstructive pulmonary disease or diagnosis of severe persistent asthma3. History of chronic renal impairment requiring hemodialysis or known or suspected to have moderate or severe renal impairment (actual or estimated creatinine clearance <50 mL/min)4. History of congestive heart failure requiring daily pharmacotherapy with symptoms consistent with New York Heart Association Class II, III, or IV within the past 12 months5. Immunocompromised status due to illness or previous organ transplant6. Current use of systemic immunosuppressive medications (except inhaled corticosteroids)7. Use of rimantadine, amantadine, zanamivir, or oseltamivir in the past 7 days8. Immunized against influenza with live attenuated virus vaccine (FluMist®) in the previous 21 days9. Clinical evidence of active bacterial infection at any body site requiring therapy with oral or systemic antibiotics10. Clinically significant signs of acute respiratory distress11. Clinically significant signs of acute cardiac disease12. Screening ECG which suggests acute ischemia or presence of medically significant dysrhythmia 13. Presence of a chronic disease or illness(es) with either clinical or historical evidence of recent exacerbation of such disease(s) or illness(es) or lack of control of such disease(s) or illness(es)14. History of hepatitis B, hepatitis C, or human immunodeficiency virus infection15. History of alcohol abuse or drug addiction within 1 year prior to admission in the study16. Participation in a study of any investigational drug within the last 30 days 17. Positive urine pregnancy test.
研究者
相似试验
尚未招募
2 期
To evaluate the effects on time to clinical stability associated with treatment with peramivir administered intravenously compared to oral oseltamivir in adults hospitalized with acute serious or potentially life-threatening influenzaLife threatening comorbidities suchs as COPD, congestive heart failure and diabetes.Respiratory - Other respiratory disorders / diseasesRespiratory - Chronic obstructive pulmonary diseaseMetabolic and Endocrine - DiabetesInfluenzaACTRN12607000282482BioCryst Pharmaceuticals Inc.120
进行中（未招募）
1 期
A phase II, Multicenter, Randomised, Double-Mask, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenzancomplicated Acute InfluenzaMedDRA version: 8.1 Level: LLT Classification code 10059637 Term: Influenza antibody testEUCTR2006-005196-17-GBBioCryst Pharmaceuticals, Inc.300
招募中
2 期
A Phase 2 Study to Assess the Efficacy and Safety of KHK4951 in Patients with Diabetic Macular EdemaJPRN-jRCT2031230400Takigawa Sotaro117
招募中
2 期
A Phase 2 Study to Assess the Efficacy and Safety of KHK4951 in Patients with Neovascular Age-Related Macular DegeneratioJPRN-jRCT2031230401Takigawa Sotaro117
进行中（未招募）
1 期
A randomized, double-masked, multicenter, phase II study assessing the safety and efficacy of two concentrations of ranibizumab (intravitreal injections) compared with non-treatment control for the treatment of diabetic macular edema with center involvement - RESOLVEEUCTR2005-000487-11-GBovartis Pharma Services AG